Last month, the US Food and Drug Administration (FDA) announced that it would be removing the strictest "black box" warnings from menopause hormone therapy. We explore the reasons for this decision, and whether menopause hormone therapy is safe for women going through perimenopause and menopause. We also look at the impact of menopause on women at work and whether the FDA’s ruling on MHT contributes to the destigmatisation of hormone therapy.

Image credit: Shutterstock

Produced by: Tee Shiao Eek

Presented by: Tee Shiao Eek

This and more than 60,000 other podcasts in your hand. Download the all new BFM mobile app.

Categories:  Women in Business,  managing disease,  health policy,  wellness,  the workplace

Tags:  the bigger picture,  health and living,  menopause,  hormone replacement therapy,  perimenopause,  menopausal hormone therapy,